Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42()()

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States. This study was aimed at evaluating the efficacy of AR-42 (formerly OSU-HDAC42), a novel histone deacetylase (HDAC) inhibitor currently in clinical trials, in suppressing tumor growth and...

Descripción completa

Detalles Bibliográficos
Autores principales: Henderson, Sally E., Ding, Li-Yun, Mo, Xiaokui, Bekaii-Saab, Tanios, Kulp, Samuel K., Chen, Ching-Shih, Huang, Po-Hsien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2016
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126135/
https://www.ncbi.nlm.nih.gov/pubmed/27889645
http://dx.doi.org/10.1016/j.neo.2016.10.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126135/
https://www.ncbi.nlm.nih.gov/pubmed/27889645
http://dx.doi.org/10.1016/j.neo.2016.10.003

Ejemplares similares